Post Hepatitis B vaccination sero-conversion among health care workers in the Cape Coast Metropolis of Ghana.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
02
2019
accepted:
17
06
2019
entrez:
29
6
2019
pubmed:
30
6
2019
medline:
23
2
2020
Statut:
epublish
Résumé
HBV vaccine is known to offer protection against transmission of HBV infection. Health care workers are mandated to have this vaccination as part of their occupational health safety measures. Post vaccination response data for HCWs in our setting is not available. This study therefore aimed to evaluate the anti-HBs titre levels after Hepatitis B vaccination among HCWs from selected heath facilities in the Cape Coast Metropolis, Ghana. A multicenter (3 selected sites) analytical cross-sectional study involving 711 HCWs was conducted. Five (5mls) of blood samples were collected from each study participant and the serum used for HBV immunological profile testing anti-HBs quantification by ELISA test (Fortress Diagnostics Limited, Northern Ireland, United Kingdom). Data analyses were performed using Stata version 14.0 software (STATA Corp, Texas USA). The median age of participants was 29 years (IQR = 26-35 years). Majority (80.9%, n = 575) took their vaccination from Government health facilities compared with 19.1% (n = 136) from private vaccination sources. A total of 7 (3 males and 4 females) were found to be HBsAg positive giving prevalence of 1%. In all, 8.2% (n = 58) of the HCWs had anti-HBs titre levels <10IU/ml giving a sero-protection rate of 91.8%. HCWs who received 3 doses of HBV vaccine were more likely to be sero-protected as compared to those who received only one dose in multivariate analysis (aOR = 3.39, 95%CI: 1.08-10.67), p<0.037). Gender, cigarette smoking and alcohol consumption were not found to be associated with sero-protection. There is a high HBV vaccine efficacy among HCWs in the Cape Coast Metropolis of Ghana with higher prevalence of anti-HBs titre level associated with full vaccine dose adherence. Post vaccination antibody titre determination could be an integral part of HBV vaccination protocol for HCWs in Ghana.
Sections du résumé
BACKGROUND
HBV vaccine is known to offer protection against transmission of HBV infection. Health care workers are mandated to have this vaccination as part of their occupational health safety measures. Post vaccination response data for HCWs in our setting is not available. This study therefore aimed to evaluate the anti-HBs titre levels after Hepatitis B vaccination among HCWs from selected heath facilities in the Cape Coast Metropolis, Ghana.
METHODS
A multicenter (3 selected sites) analytical cross-sectional study involving 711 HCWs was conducted. Five (5mls) of blood samples were collected from each study participant and the serum used for HBV immunological profile testing anti-HBs quantification by ELISA test (Fortress Diagnostics Limited, Northern Ireland, United Kingdom). Data analyses were performed using Stata version 14.0 software (STATA Corp, Texas USA).
RESULTS
The median age of participants was 29 years (IQR = 26-35 years). Majority (80.9%, n = 575) took their vaccination from Government health facilities compared with 19.1% (n = 136) from private vaccination sources. A total of 7 (3 males and 4 females) were found to be HBsAg positive giving prevalence of 1%. In all, 8.2% (n = 58) of the HCWs had anti-HBs titre levels <10IU/ml giving a sero-protection rate of 91.8%. HCWs who received 3 doses of HBV vaccine were more likely to be sero-protected as compared to those who received only one dose in multivariate analysis (aOR = 3.39, 95%CI: 1.08-10.67), p<0.037). Gender, cigarette smoking and alcohol consumption were not found to be associated with sero-protection.
CONCLUSION
There is a high HBV vaccine efficacy among HCWs in the Cape Coast Metropolis of Ghana with higher prevalence of anti-HBs titre level associated with full vaccine dose adherence. Post vaccination antibody titre determination could be an integral part of HBV vaccination protocol for HCWs in Ghana.
Identifiants
pubmed: 31251790
doi: 10.1371/journal.pone.0219148
pii: PONE-D-19-05974
pmc: PMC6599216
doi:
Substances chimiques
Hepatitis B Antibodies
0
Hepatitis B Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0219148Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Trans R Soc Trop Med Hyg. 2015 Mar;109(3):203-8
pubmed: 25636951
Biomed Res Int. 2017;2017:1327492
pubmed: 29082237
BMC Infect Dis. 2016 Mar 18;16:130
pubmed: 26987556
BMC Infect Dis. 2017 Dec 20;17(1):786
pubmed: 29262783
MMWR Recomm Rep. 2013 Dec 20;62(RR-10):1-19
pubmed: 24352112
Sci Rep. 2016 Jun 21;6:27251
pubmed: 27324884
Hepat Mon. 2014 Jan 12;14(1):e13625
pubmed: 24497878
Int J Infect Dis. 2013 Nov;17(11):e1078-9
pubmed: 23810225
Jundishapur J Microbiol. 2015 Mar 21;8(3):e19579
pubmed: 25861435
Vaccine. 2012 Feb 21;30(9):1644-9
pubmed: 22245310
Hum Vaccin. 2010 Feb;6(2):212-8
pubmed: 19946212
BMC Infect Dis. 2018 Sep 21;18(1):474
pubmed: 30241503
Vaccine. 2019 Jan 3;37(1):145-151
pubmed: 30449632
J Infect Dis. 2013 Feb 1;207(3):402-10
pubmed: 23175769
Eur J Epidemiol. 2001;17(2):150-6
pubmed: 11599689
J Infect Public Health. 2014 Nov-Dec;7(6):534-41
pubmed: 25151657
MMWR Recomm Rep. 2011 Nov 25;60(RR-7):1-45
pubmed: 22108587
BMC Health Serv Res. 2017 Apr 5;17(1):254
pubmed: 28381257
Hepat Res Treat. 2017;2017:6470658
pubmed: 28751988
Vaccine. 2018 Aug 6;36(32 Pt B):4851-4860
pubmed: 29970299
Hepatol Res. 2006 May;35(1):1-2
pubmed: 16890177
Front Immunol. 2018 May 15;9:1035
pubmed: 29868000
J Infect Dis. 2016 Jul 1;214(1):16-22
pubmed: 26802139
Clin Liver Dis. 2016 Nov;20(4):607-628
pubmed: 27742003
Hum Vaccin Immunother. 2012 Jul;8(7):896-904
pubmed: 22777097
PLoS One. 2018 Jul 16;13(7):e0200157
pubmed: 30011286